HIV ART Cost Projections for Zimbabwe to 2026

Time-driven activity-based costing data estimates provider costs for adult and adolescent antiretroviral therapy in Zimbabwe. The analysis is based on over 2,500 provider-recipient observations collected from 11 facilities across four levels of care. It projects national ART costs rising from $168.66 million in 2022 to $192.44 million by 2026.

Use Cases

• Model future ART budget requirements using projected national costs to 2026
• Compare cost structures by facility level, where primary care facilities bore 75% of costs
• Analyze cost drivers such as laboratory services ($30.72) versus medicines ($27.98) for adult ART
• Evaluate cost-efficiency of task-shifting strategies within HIV care pathways

Strengths

• Analysis grounded in over 2,500 direct provider-recipient observations
• Cost projections validated by national level stakeholders
• Provides granular cost breakdowns, e.g., $57.05 for adult ART initiation and $62.70 for paediatric

Limitations

• Dataset scale is 5.5 KB, indicating a highly aggregated summary rather than raw observational data
• Limited to 11 facilities in Zimbabwe, may not represent all national variation
• Projections depend on 2022 baseline and specific modeling assumptions

Provenance

Source

Juliet Gamuchirai Nyamasve via figshare

Collection Method

Descriptive cross-sectional study using time-driven activity-based costing (TDABC) with data collected via standardized instruments

Time Range

2022 baseline with projections to 2026

Freshness

Projections extend to 2026, with last update in March 2026.

Geography

Zimbabwe (11 facilities across four levels of care)